150 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34515877 | Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies. | 2022 Feb | 1 |
2 | 35170228 | Effect of food on capsule and granule formulations of selumetinib. | 2022 Apr | 1 |
3 | 35171389 | Selumetinib: a selective MEK1 inhibitor for solid tumor treatment. | 2022 Feb 16 | 4 |
4 | 35210278 | ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. | 2022 Mar | 1 |
5 | 35246426 | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. | 2022 Mar 4 | 2 |
6 | 35250023 | Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2022 Mar 7 | 2 |
7 | 35406545 | Inhibition of MACC1-Induced Metastasis in Esophageal and Gastric Adenocarcinomas. | 2022 Mar 31 | 1 |
8 | 35410754 | A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. | 2022 Apr | 2 |
9 | 33273059 | AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. | 2021 Feb | 3 |
10 | 33405090 | Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. | 2021 Jun | 2 |
11 | 33536190 | Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies. | 2021 Apr | 1 |
12 | 33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | 2021 Oct 1 | 1 |
13 | 33683166 | Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. | 2021 May | 1 |
14 | 33808483 | Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico. | 2021 Mar 30 | 1 |
15 | 33903938 | Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. | 2021 Aug | 2 |
16 | 33978635 | Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo. | 2021 Jan-Dec | 1 |
17 | 34196005 | Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens. | 2021 Nov | 2 |
18 | 34680330 | Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity. | 2021 Oct 15 | 1 |
19 | 34831012 | MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. | 2021 Nov 22 | 1 |
20 | 32108293 | Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. | 2020 Apr | 3 |
21 | 32504375 | Selumetinib: First Approval. | 2020 Jun | 3 |
22 | 32629964 | The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. | 2020 Jun 30 | 2 |
23 | 32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov | 1 |
24 | 33099927 | Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells. | 2020 Jul-Aug | 1 |
25 | 30317534 | Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. | 2019 Jun | 3 |
26 | 30972766 | MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. | 2019 Sep | 1 |
27 | 31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | 2019 Jul | 1 |
28 | 31200828 | Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219. | 2019 Jul | 1 |
29 | 31409052 | Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. | 2019 Aug 12 | 1 |
30 | 28833380 | Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials. | 2018 Jan | 1 |
31 | 28986121 | A cellular threshold for active ERK1/2 levels determines Raf/MEK/ERK-mediated growth arrest versus death responses. | 2018 Jan | 1 |
32 | 29216787 | MEK inhibitors under development for treatment of non-small-cell lung cancer. | 2018 Jan | 1 |
33 | 29526823 | Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. | 2018 Jun | 1 |
34 | 29528792 | Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). | 2018 Apr 20 | 3 |
35 | 29737325 | The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2018 May 8 | 2 |
36 | 29915160 | The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. | 2018 Aug 15 | 1 |
37 | 30414267 | Effects of Erythromycin on the Proliferation and Apoptosis of Cultured Nasal Polyp-Derived Cells and the Extracellular Signal-Regulated Kinase (ERK)/Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. | 2018 Nov 10 | 1 |
38 | 27889832 | Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials. | 2017 Feb | 1 |
39 | 28019010 | Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects. | 2017 May | 1 |
40 | 28212559 | The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo. | 2017 Mar 28 | 2 |
41 | 28264648 | A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. | 2017 Mar 6 | 3 |
42 | 28283692 | Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. | 2017 Jun | 2 |
43 | 28326681 | Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade Gliomas. | 2017 May | 2 |
44 | 28385507 | Discovery of a cobalt complex with high MEK1 binding affinity. | 2017 May 15 | 1 |
45 | 28424891 | A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. | 2017 Oct | 3 |
46 | 28791489 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. | 2017 Nov | 1 |
47 | 28819429 | MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines. | 2017 | 3 |
48 | 28849200 | Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis. | 2017 Oct | 3 |
49 | 28931905 | Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. | 2017 Sep 20 | 2 |
50 | 26446942 | A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. | 2016 Mar 1 | 3 |